|
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy Clinical research trials and VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy. VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy  VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy
For Condition: unspecified adult solid tumor, protocol specific
Status: No longer recruiting
Sponsor(s): Vion Pharmaceuticals ,
Synopsis: RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have advanced or metastatic solid tumors that have not responded to previous therapy.
Details: OBJECTIVES: I. Determine the maximum tolerated dose and safety of intratumoral live, genetically modified Salmonella typhimurium (VNP20009) in patients with refractory, superficial solid tumors. II. Determine the efficacy of VNP20009 in these patients. PROTOCOL OUTLINE: This is a dose-escalation study. Patients receive intratumorally injected live, genetically modified Salmonella typhimurium (VNP20009) on day 0. The tumor is biopsied on day 14. Cohorts of 3-6 patients receive escalating doses of VNP20009 until the maximum tolerated dose (MTD) or the optimal biologic dose (OBD) is determined. The MTD is defined as the highest dose in which no more than 1 patient in a cohort of 6 experiences dose-limiting toxicity (DLT). The OBD is defined as the dose at which 3-6 patients of a cohort have greater than 10 million colony-forming units of VNP20009 per gram in the tumor biopsy. Prior to reaching the OBD, 2 to 3 additional patients may be entered at a previous dose level shown to be safe to undergo biopsy of the injected lesion between days 5 and 8. Patients are assessed for systemic tumor response 4-5 weeks after treatment. If the injected lesion is stable or responding, and non-injected lesions have not grown, patients may receive up to 2 additional courses of treatment. Patients receive one of the following antibiotic regimens upon evidence of progressive disease, DLT, or discontinuation from the study: First line: Ciprofloxacin IV or orally every 12 hours on day 1 then orally twice a day for 18 days Second line: Ceftriaxone IV on day 1 then cefixime orally for 16 days Third line: Co-trimoxazole orally twice a day for 21 days Patients are followed for an additional 4 weeks after initiation of antibiotic therapy. PROJECTED ACCRUAL: A total of 12-40 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven advanced or metastatic solid tumors that have failed prior therapy and no other therapy is available - At least 1 tumor mass of a size that makes intratumoral injection feasible and biopsy or fine needle aspiration possible - Major surgery for cancer not required - No lymphoma - No concurrent brain metastases (previously treated brain metastases with no evidence of recurrence allowed) --Prior/Concurrent Therapy-- - Biologic therapy: At least 6 months since any bone marrow transplantation; At least 4 weeks since prior biologic therapy and recovered; No other concurrent biologic therapy; No prior allogenic transplants - Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered; No concurrent chemotherapy - Endocrine therapy: At least 2 weeks since prior hormonal therapy; No concurrent steroids - Radiotherapy: At least 4 weeks since prior radiotherapy and recovered; No concurrent radiotherapy - Surgery: See Disease Characteristics; At least 2 weeks since prior surgery and recovered; No artificial implant (e.g., heart valves, prosthetic hips or knees); No prior splenectomy - Other: No other concurrent antibiotics; No concurrent immunosuppressives; No concurrent medications that directly or indirectly suppress the immune system --Patient Characteristics-- - Age: 18 and over - Menopausal status: Not specified - Performance status: Karnofsky 70-100% OR ECOG 0-1 - Life expectancy: At least 3 months - Hematopoietic: Granulocyte count at least 1,500/mm3; Platelet count at least 100,000/mm3; Hematocrit at least 30% (transfusion allowed); No bleeding disorder - Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN); ALT/AST no greater than 1.5 times ULN (no greater than 3 times ULN in the presence of liver metastases); Alkaline phosphatase no greater than 1.5 times ULN (no greater than 3 times ULN in the presence of liver metastases); PT and aPTT no greater than 1.5 times ULN; No end stage liver disease - Renal: Creatinine no greater than 1.5 times ULN; No urinary tract stones; No end stage renal disease - Cardiovascular: No known valvular disease or ischemic peripheral vascular disease; No clinically significant atherosclerotic disease or arterial aneurysm(s); No unstable angina; No active coronary artery disease requiring medication; No myocardial infarction within the past 6 months; No congenital heart failure or cardiac arrhythmia requiring medication - Pulmonary: No severe oxygen-dependent chronic obstructive pulmonary disease - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; Permanent central venous catheters and other indwelling devices allowed if easily removed or replaced; No gallstones; No active infection; No Salmonella infection within past 6 months; No fever caused by tumor or unknown cause (daily temperature no greater than 38 degrees C); HIV negative; No immunodeficiency; No other life-threatening illness; No commercial food handler, day-care worker, or health-care worker who plans to continue employment during protocol treatment; No allergy to quinolone or cephalosporin antibiotics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MarioSznol, Study Chair, Vion Pharmaceuticals
Mary Crowley Medical Research Center
Dallas, Texas, 75246
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
Additional Information:
Study ID Numbers: CDR0000067446; VION-CLI-005,NCI-V99-1581
Study Start Date: August 1999
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004216
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
2. Lidocaine Patch in Treating Cancer Patients with Neuropathic Pain After Surgery
3. Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer
4. Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
5. MEN-10755 in Treating Patients With Solid Tumors
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other Texas Clinical Trials
Other Dallas Clinical Trials
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy
|
|
|
|
|
|
|
|
